Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
diagnostics
5
×
indiana blog main
indiana top stories
life sciences
national
5
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
merck
novartis
abbvie
alzheimer's disease
amgen
cancer
deals
gilead sciences
immunotherapy
medicare
pfizer
startups
What
bio
drug
roundup
new
acquisitions
biggest
ceo
patients
way
advantages
albert
approval
bar
biogen’s
biopharmaceutical
bourla
brings
build
buy
cancer
centers
companies
company
company’s
convo
crispr
cut
daniel
debut
depression
dyne’s
earlier
event
expect
failures
future
gamble
genetic
gilead
guesswork
Language
unset
unknown
Current search:
diagnostics
×
national
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?